Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.

Abstract : C-reactive protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal estrogen replacement therapy (ERT) increases CRP levels, but the effect of transdermal ERT is not well documented. CRP, interleukine-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were evaluated in a randomised study of 196 healthy postmenopausal women, who were allocated to receive continuous oral estradiol-1beta, (n=63) or transdermal estradiol-1beta, (n=68) both combined with micronised progesterone, or place-bo (n=65). Oral estrogen increased CRP levels compared with both placebo (p=0.010) and transdermal estrogen (p=0.004) at 6 months. There was no significant effect of transdermal estrogen on CRP levels compared with placebo (p=0.997). No significant difference was found in the median changes for IL-6 and TNF-alpha between the three treatment groups. In conclusion, transdermal estrogen has no significant effect on CRP levels at 6 months, but CRP concentrations increased significantly with oral estrogen although no changes in cytokine levels were detected. The clinical relevance of these effects remains to be determined.
Type de document :
Article dans une revue
Thrombosis and Haemostasis, Schattauer, 2003, 90 (1), pp.124-31. 〈10.1267/THRO03010124〉
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00722269
Contributeur : Ghislaine Calvez <>
Soumis le : mercredi 1 août 2012 - 10:23:21
Dernière modification le : mercredi 10 janvier 2018 - 14:42:02

Identifiants

Collections

Citation

Karine Lacut, Emmanuel Oger, Grégoire Le Gal, Marie-Thérèse Blouch, Jean-François Abgrall, et al.. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.. Thrombosis and Haemostasis, Schattauer, 2003, 90 (1), pp.124-31. 〈10.1267/THRO03010124〉. 〈hal-00722269〉

Partager

Métriques

Consultations de la notice

153